Calcimedica, inc.CALC.US Overview

US StockHealthcare

(No presentation for CALC)

Overview AI Analysis AI Earnings Summary Financials Financial Forecast Stock Sentimental Institutions TradingView Chart

CALC Overall Performance

CALC AI Analysis & Strategy

CALC Recent Performance

3.06%

Calcimedica, inc.

0.81%

Avg of Sector

-1.14%

S&P500

CALC PowerScanner

CALC Key Information

CALC Valuation Metrics

CALC Earnings Table

CALC Profile

CalciMedica, Inc., a clinical-stage biotechnology company, focuses on developing therapies for life-threatening inflammatory diseases with unmet needs. Its proprietary technology targets the inhibition of calcium release-activated (CRAC) channels designs to modulate the immune response and protect against tissue cell injury in life-threatening inflammatory diseases. Its lead product candidate is Auxora, a proprietary intravenous-formulated CRAC channel inhibitor for the treatment of acute pancreatitis, asparaginase-associated acute pancreatitis, and acute kidney injury. The company is based in La Jolla, California.